Press Release Archives
Lilly to Host Conference Call to Discuss Trial Design of New Solanezumab Phase 3 Study
Jul 3, 2013
INDIANAPOLIS, July 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a conference call to discuss key elements of the trial design for EXPEDITION3, its third Phase 3 trial for solanezumab. Lilly's solanezumab is a monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease. The conference call will be held from 9:00 a.m. to 9:45 a.m. EDT on Friday, July 12, 2013.
A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm. Subsequently, a replay of the presentation will be available on this same website.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers —through medicines and information —for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. P-LLY
This press release contains certain forward-looking statements about solanezumab. This release reflects Lilly's current beliefs; however, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date, or that solanezumab will be approved as a product or will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
(317) 224-5331, firstname.lastname@example.org - Stefanie Prodouz (Media)
(317) 655-6874, email@example.com - Philip Johnson (Investors)
SOURCE Eli Lilly and Company